(ASX:KZA)
We aspire to help patients and clinicians confront the most challenging cancers in modern medicine.
Kazia's drug candidates are designed to treated diseases such as brain cancer, renal cancer, and liver cancer, which are poorly served by existing therapies.
Market Reports /
by Peter Milios -
2 years ago
31 Jan 2023 - Australian shares fluctuated on Tuesday with a 0.4 per cent gain and later 0.2 per cent loss. Consumer stocks led the gains, up 2.3 per cent, while tech stocks weighe…
Market Reports /
by Peter Milios -
2 years ago
31 Jan 2023 - Retail sales in Australia fell 3.9% in December, surprising expectations for a 0.2% decline. The ABS Head of Retail Statistics noted that the fall follows 11 consecut…
Market Reports /
by Peter Milios -
2 years ago
01 Dec 2022 - Eight out of the eleven sectors have finished higher today, with big results from Materials, Utilities and Communication Services, whilst the sectors that were in the…
Market Reports /
by Peter Milios -
2 years ago
01 Dec 2022 - The ASX has reacted positively to overnight news from the Federal Reserve. Chair Jerome Powell has confirmed the central bank will slow the pace of interest rate rise…
Market Reports /
by Lauren Hayes -
2 years ago
28 Oct 2022 - Disappointing earnings from major US tech companies, including Meta, Apple and Amazon, has caused the Information Technology sector on the ASX to fall by 2.17 per cen…
Market Reports /
by Paul Sanger -
2 years ago
08 Aug 2022 - The labour market added 528,000 jobs in July, easily beating a Dow Jones estimate of a 258,000 increase. The unemployment rate ticked down to 3.5 per cent, below the …
Market Reports /
by Melissa Darmawan -
2 years ago
07 Jul 2022 - Despite the materials sector leading the gains, the sector offset losses in industrials, information technology, property, and communication services, the main coal m…
Market Reports /
by Melissa Darmawan -
2 years ago
07 Jul 2022 - Australian stocks have rebounded, lifted by the material sector. Gains in consumer staples and discretionary stocks have offset losses in information technology, whil…
Market Reports /
by Melissa Darmawan -
2 years ago
11 May 2022 - Wall St closed mixed lifted by information tech and M&A news in the biotech sector as dip buyers emerge ahead of the next CPI print. Shanghai stocks bucked the trend …
Company News /
by Adrian Tan -
3 years ago
03 Dec 2021 - Kazia Therapeutics (ASX:KZA) has announced positive results from its Phase II study into the treatment of glioblastoma with paxalisib.
Company News /
by Rachael Jones -
4 years ago
09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
Interviews /
by Rachael Jones -
4 years ago
27 Apr 2020 - Kazia Therapeutics (ASX:KZA) CEO & MD, Dr. James Garner talks about its Phase II interim results for its glioblastoma drug candidate paxasilib, its pivotal GBM AGILE …
Company Presentations /
by -
6 years ago
22 Oct 2018 - Kazia Therapeutics Limited (ASX:KZA) CEO and Executive Director Dr James Garner provides an update on the company's two clinical stage drug development candidates for…
Interviews /
by Rachael Jones -
6 years ago
22 Oct 2018 - Kazia Therapeutics Limited (ASX:KZA) CEO and Executive Director Dr James Garner provides an update on the company's two clinical stage drug development candidates for…
